Mira Pharmaceuticals (MIRA) Cash & Equivalents (2022 - 2025)

Mira Pharmaceuticals has reported Cash & Equivalents for 4 years, with the latest figure at $6.3 million in Q4 2025.

• Quarterly Cash & Equivalents rose 124.04% year-over-year to $6.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.3 million (up 124.04% YoY) and the FY2025 annual result came in at $6.3 million, up 124.04% from the prior year.
• Cash & Equivalents advanced to $6.3 million in Q4 2025 per MIRA's latest filing, from $2.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $6.3 million in Q4 2025 and troughed at $1349.0 in Q1 2023.
• A 4-year average of $2.5 million and a median of $2.6 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents surged 261478.58% in 2024, then tumbled 65.81% in 2025.
• Over 4 years, Cash & Equivalents stood at $350978.0 in 2022, then surged by 1211.35% to $4.6 million in 2023, then sank by 38.45% to $2.8 million in 2024, then soared by 124.04% to $6.3 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $6.3 million, $2.6 million, and $730475.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.